Essential Hypertension. Therapeutic Trial of Veriloid, a New Extract of Veratrum viride.

Abstract

Trial of Veriloid revealed it to be an active hypotensive agent when admd. acutely in 10 hypertensive patients, or chronically for periods as long as 5 months in 25 such patients. Meticulous regulation of dosage was necessary to obtain significant hypo-tensive effects without nausea and vomiting. After several weeks of continuous therapy it was frequently necessary to reduce the dosage in order to avoid such side effects. Nevertheless, relative to its hypotensive effects Veriloid seemed to produce fewer toxic reactions than any other oral prepn. of V. viride presently available.